KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Treasury Shares: 2010-2024

Historic Treasury Shares for Regeneron Pharmaceuticals (REGN) over the last 11 years, with Dec 2024 value amounting to $15.2 billion.

  • Regeneron Pharmaceuticals' Treasury Shares rose 26.44% to $17.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $17.9 billion, marking a year-over-year increase of 26.44%. This contributed to the annual value of $15.2 billion for FY2024, which is 20.76% up from last year.
  • Regeneron Pharmaceuticals' Treasury Shares amounted to $15.2 billion in FY2024, which was up 20.76% from $12.6 billion recorded in FY2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' Treasury Shares peaked at $28.2 million during FY2024, and registered a low of $16.4 million during FY2020.
  • For the 3-year period, Regeneron Pharmaceuticals' Treasury Shares averaged around $25.4 million, with its median value being $25.5 million (2023).
  • Data for Regeneron Pharmaceuticals' Treasury Shares shows a peak YoY soared of 793.81% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Regeneron Pharmaceuticals' Treasury Shares stood at $6.6 billion in 2020, then grew by 24.91% to $8.3 billion in 2021, then rose by 25.33% to $10.4 billion in 2022, then grew by 21.32% to $12.6 billion in 2023, then increased by 20.76% to $15.2 billion in 2024.